Home › Stargardt Disease › NCT06445322

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Prescreening Study to Identify Potential Participants With ABCA4-related Retinopathy for ACDN-01 Clinical Trials

Who can join

Ages 5 and older · All sexes

Key Inclusion Criteria:

* Presence of mutations in the ABCA4 gene
* ABCA4 retinopathy phenotype (Stargardt disease type 1 or cone-rod dystrophy)

Key Exclusion Criteria:

* The presence of pathogenic or likely pathogenic mutations in other genes known to cause cone-rod dystrophy or Stargardt maculopathy
* Retinal disease other than ABCA4-related retinopathy
* Presence of a medical condition (systemic or ophthalmic), psychiatric condition, including substance abuse disorder, or physical examination or laboratory finding that may in the opinion of the principal investigator and sponsor preclude adherence to the scheduled study visits, safe participation in the study, or affect the results of the study.

About the study

This is an observational prescreening study. Individuals who are eligible for prescreening will undergo testing procedures that may be used to determine eligibility in ACDN-01 clinical trials.

What is being tested

• Prescreening Assessments (diagnostic test)

Sponsor: Ascidian Therapeutics, Inc · Participants: 50 · Started: Jun 20, 2024

Contact the study team

• Associate Director, Clinical Operations · Phone: 207-573-0412

Official record on ClinicalTrials.gov — NCT06445322

Locations in the U.S.

Conditions

• Stargardt Disease
• Cone-Rod Dystrophies

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.